Recovery Action held by the Legislation/Judiciary Committee

Even if it is presented at the New Year's plenary session, delay in processing is inevitable if some members oppose it

The ruling party introduces a bill to promote the focus and makes all-out efforts to deal with it

The refund system will be promoted as scheduled

The recovery system of drug prices bill, which drew attention from the government and domestic and foreign pharmaceutical companies, has been held by the National Assembly's Legislation and Judiciary Committee and is in trouble to deal with it.

 

As it was excluded from the Legislation and Judiciary Committee agenda again during the extraordinary National Assembly in December last year, even the screening committee failed to rise, and there are concerns that it will not be passed even if it is barely introduced this year.

 

The second subcommittee of the Legislation and Judiciary Committee, which is in charge of reviewing other standing committees' resolutions, tends to be rarely reviewed once handed over, so it is often called the "black hole in the bill" and the "tomb of the bill." On the 3rd, the National Assembly's Legislation and Judiciary Committee did not review the alternative of the chairman of the National Health Insurance Act on the resolution at a plenary session held within last year's extraordinary session.

 

Some pharmaceutical and legal circles are strongly opposed to the review and processing of bills on the redemption and refund of drug prices, which reportedly affected the unknown agenda of the Legislation and Judiciary Committee.

 

Some say that it will not be easy to deal with even if a plenary session of the Legislation and Judiciary Committee is held at the extraordinary National Assembly to be held in the new year and a revision to the Health Insurance Act, which includes a bill to return and refund drug prices, is on the agenda.

 

It could be held by the Legislation and Judiciary Committee if some members of the Legislation and Judiciary Committee hold the bill at the plenary session or hand it over to a second subcommittee that examines other standing committee bills.If it is handed over to the second subcommittee on bills, it is not clear whether it will be able to obtain a proper opportunity for examination until the end of its 21st term in the National Assembly.

 

The government and the ruling party plan to continue to urge the opposition party and the judiciary committee to review the agenda ahead of the need for a bill to recover and refund drug prices.

 

The MOHW is expected to push ahead with the introduction of a refund system as planned through the revision of the health insurance care benefit rules and related notices reported to the Health Insurance Policy Deliberation Committee late last year.

 

An official from the ruling party of the National Assembly's Health and Welfare Committee said, "The Pharmaceutical Affairs Committee and the opposition party are boycotting the agenda, even though the Restitution and Refund Act is a bill that settles and compensates for unnecessary damage to both pharmaceutical companies and the NHIS.

 

Because of this, bills such as regulations on office managers' illegal hospitals, illegal pharmacies lending licenses, and mandatory identification of patient health insurance are also delayed." The official said, "The ruling party plans to select the revision of the health insurance law as an intensive promotion bill and continue to urge it to be processed.

 

I understand that the MOHW is also repeatedly appealing to the Legislation and Judiciary Committee to pass the bill."